{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T19:01:59Z","timestamp":1793991719481,"version":"4.8.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,4,9]],"date-time":"2021-04-09T00:00:00Z","timestamp":1617926400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,4,9]],"date-time":"2021-04-09T00:00:00Z","timestamp":1617926400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Transl Psychiatry"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Cannabis is known to produce acute, transient psychotic-like experiences. However, it is unclear whether cannabis disproportionately increases the risk of specific types of psychotic experiences and whether genetic predisposition influences the relationship between cannabis use and psychotic experiences. In this cross-sectional study of 109,308 UK Biobank participants, we examined how schizophrenia polygenic risk modulates the association between self-reported cannabis use and four types of self-reported psychotic experiences (auditory hallucinations, visual hallucinations, persecutory delusions, and delusions of reference). Cohort-wide, we found a strong, dose-dependent relationship between cannabis use and all four types of psychotic experiences, especially persecutory delusions. Cannabis users\u2019 psychotic experiences tended to be earlier-onset and cause greater distress than non-users\u2019, but were not more likely to lead to help-seeking. Participants with high schizophrenia polygenic risk scores showed stronger associations between cannabis use and auditory hallucinations, visual hallucinations, and delusions of reference, as well as psychotic experiences overall. For instance, cannabis ever-use was associated with 67% greater adjusted odds of delusions of reference among individuals in the top fifth of polygenic risk, but only 7% greater adjusted odds among the bottom fifth. Our results suggest that cannabis use is a predictive risk factor for psychotic experiences, including early-onset and distressing experiences. Individuals genetically predisposed to schizophrenia may be especially vulnerable to psychotic experiences as a result of using cannabis, supporting a long-postulated hypothesis. This study exemplifies the utility of population-scale biobanks for elucidating gene-by-environment interactions relating substance use to neuropsychiatric outcomes and points to the translational potential of using polygenic risk scores to inform personalized harm reduction interventions.<\/jats:p>","DOI":"10.1038\/s41398-021-01330-w","type":"journal-article","created":{"date-parts":[[2021,4,9]],"date-time":"2021-04-09T12:03:40Z","timestamp":1617969820000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":61,"title":["Cannabis, schizophrenia genetic risk, and psychotic experiences: a cross-sectional study of 109,308 participants from the UK Biobank"],"prefix":"10.1038","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6061-0239","authenticated-orcid":false,"given":"Michael","family":"Wainberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace R.","family":"Jacobs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"di Forti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shreejoy J.","family":"Tripathy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,4,9]]},"reference":[{"key":"1330_CR1","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/j.biopsych.2015.08.001","volume":"79","author":"SH Gage","year":"2016","unstructured":"Gage, S. H., Hickman, M. & Zammit, S. Association between cannabis and psychosis: epidemiologic evidence. Biol. Psychiatry 79, 549\u2013556 (2016).","journal-title":"Biol. Psychiatry"},{"key":"1330_CR2","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1080\/08897077.2014.995332","volume":"36","author":"KS Bagot","year":"2015","unstructured":"Bagot, K. S., Milin, R. & Kaminer, Y. Adolescent initiation of cannabis use and early-onset psychosis. Subst. Abus. 36, 524\u2013533 (2015).","journal-title":"Subst. Abus."},{"key":"1330_CR3","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1001\/archgenpsychiatry.2011.5","volume":"68","author":"M Large","year":"2011","unstructured":"Large, M., Sharma, S., Compton, M. T., Slade, T. & Nielssen, O. Cannabis use and earlier onset of psychosis: a systematic meta-analysis. Arch. Gen. Psychiatry 68, 555\u2013561 (2011).","journal-title":"Arch. Gen. Psychiatry"},{"key":"1330_CR4","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/S2215-0366(19)30174-9","volume":"6","author":"NA Gillespie","year":"2019","unstructured":"Gillespie, N. A. et al. High-potency cannabis and incident psychosis: correcting the causal assumption. Lancet Psychiatry 6, 464 (2019).","journal-title":"Lancet Psychiatry"},{"key":"1330_CR5","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.1038\/sj.npp.1300496","volume":"29","author":"DC D\u2019Souza","year":"2004","unstructured":"D\u2019Souza, D. C. et al. The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: implications for psychosis. Neuropsychopharmacology 29, 1558\u20131572 (2004).","journal-title":"Neuropsychopharmacology"},{"key":"1330_CR6","doi-asserted-by":"publisher","unstructured":"Nesv\u00e5g, R. et al. Genetic and environmental contributions to the association between cannabis use and psychotic-like experiences in young adult twins. Schizophr. Bull. sbw101, https:\/\/doi.org\/10.1093\/schbul\/sbw101 (2016).","DOI":"10.1093\/schbul\/sbw101"},{"key":"1330_CR7","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1001\/jamapsychiatry.2018.2546","volume":"76","author":"NR Karcher","year":"2019","unstructured":"Karcher, N. R. et al. Genetic predisposition vs individual-specific processes in the association between psychotic-like experiences and cannabis use. JAMA Psychiatry 76, 87 (2019).","journal-title":"JAMA Psychiatry"},{"key":"1330_CR8","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1017\/thg.2020.75","volume":"23","author":"J Vaissiere","year":"2020","unstructured":"Vaissiere, J., Thorp, J. G., Ong, J.-S., Ortega-Alonso, A. & Derks, E. M. Exploring phenotypic and genetic overlap between cannabis use and schizotypy - Corrigendum. Twin Res. Hum. Genet. 23, 306 (2020).","journal-title":"Twin Res. Hum. Genet."},{"key":"1330_CR9","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1001\/jamapsychiatry.2015.0575","volume":"72","author":"JJ McGrath","year":"2015","unstructured":"McGrath, J. J. et al. Psychotic experiences in the general population: a cross-national analysis based on 31,261 respondents from 18 countries. JAMA Psychiatry 72, 697\u2013705 (2015).","journal-title":"JAMA Psychiatry"},{"key":"1330_CR10","doi-asserted-by":"publisher","unstructured":"Legge, S. E. et al. Association of genetic liability to psychotic experiences with neuropsychotic disorders and traits. JAMA Psychiatry, https:\/\/doi.org\/10.1001\/jamapsychiatry.2019.2508 (2019).","DOI":"10.1001\/jamapsychiatry.2019.2508"},{"key":"1330_CR11","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1176\/appi.ajp.2013.12060768","volume":"170","author":"S Zammit","year":"2013","unstructured":"Zammit, S. et al. Psychotic experiences and psychotic disorders at age 18 in relation to psychotic experiences at age 12 in a longitudinal population-based cohort study. Am. J. Psychiatry 170, 742\u2013750 (2013).","journal-title":"Am. J. Psychiatry"},{"key":"1330_CR12","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.1017\/S0033291712003091","volume":"43","author":"HL Fisher","year":"2013","unstructured":"Fisher, H. L. et al. Specificity of childhood psychotic symptoms for predicting schizophrenia by 38 years of age: a birth cohort study. Psychol. Med. 43, 2077\u20132086 (2013).","journal-title":"Psychol. Med."},{"key":"1330_CR13","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1093\/schbul\/sbw003","volume":"42","author":"A Marconi","year":"2016","unstructured":"Marconi, A., Di Forti, M., Lewis, C. M., Murray, R. M. & Vassos, E. Meta-analysis of the association between the level of cannabis use and risk of psychosis. Schizophr. Bull. 42, 1262\u20131269 (2016).","journal-title":"Schizophr. Bull."},{"key":"1330_CR14","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1176\/ajp.128.2.213","volume":"128","author":"MH Keeler","year":"1971","unstructured":"Keeler, M. H., Ewing, J. A. & Rouse, B. A. Hallucinogenic effects of marijuana as currently used. Am. J. Psychiatry 128, 213\u2013216 (1971).","journal-title":"Am. J. Psychiatry"},{"key":"1330_CR15","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1089\/can.2017.0052","volume":"3","author":"FS Barrett","year":"2018","unstructured":"Barrett, F. S., Schlienz, N. J., Lembeck, N., Waqas, M. & Vandrey, R. \u2018Hallucinations\u2019 following acute cannabis dosing: a case report and comparison to other hallucinogenic drugs. Cannabis Cannabinoid Res. 3, 85\u201393 (2018).","journal-title":"Cannabis Cannabinoid Res."},{"key":"1330_CR16","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/j.biopsych.2016.01.011","volume":"79","author":"M Sherif","year":"2016","unstructured":"Sherif, M., Radhakrishnan, R., D\u2019Souza, D. C. & Ranganathan, M. Human laboratory studies on cannabinoids and psychosis. Biol. Psychiatry 79, 526\u2013538 (2016).","journal-title":"Biol. Psychiatry"},{"key":"1330_CR17","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.schres.2013.06.008","volume":"148","author":"D Freeman","year":"2013","unstructured":"Freeman, D. et al. Persecutory ideation and a history of cannabis use. Schizophr. Res. 148, 122\u2013125 (2013).","journal-title":"Schizophr. Res."},{"key":"1330_CR18","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1093\/schbul\/sbu098","volume":"41","author":"D Freeman","year":"2015","unstructured":"Freeman, D. et al. How cannabis causes paranoia: using the intravenous administration of \u22069-tetrahydrocannabinol (THC) to identify key cognitive mechanisms leading to paranoia. Schizophr. Bull. 41, 391\u2013399 (2015).","journal-title":"Schizophr. Bull."},{"key":"1330_CR19","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1176\/appi.ajp.2016.15070878","volume":"173","author":"J Bechtold","year":"2016","unstructured":"Bechtold, J., Hipwell, A., Lewis, D. A., Loeber, R. & Pardini, D. Concurrent and sustained cumulative effects of adolescent marijuana use on subclinical psychotic symptoms. Am. J. Psychiatry 173, 781\u2013789 (2016).","journal-title":"Am. J. Psychiatry"},{"key":"1330_CR20","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1001\/jamapsychiatry.2015.1131","volume":"72","author":"L French","year":"2015","unstructured":"French, L. et al. Early cannabis use, polygenic risk score for schizophrenia and brain maturation in adolescence. JAMA Psychiatry 72, 1002\u20131011 (2015).","journal-title":"JAMA Psychiatry"},{"key":"1330_CR21","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1093\/schbul\/sbn108","volume":"34","author":"C Henquet","year":"2008","unstructured":"Henquet, C., Di Forti, M., Morrison, P., Kuepper, R. & Murray, R. M. Gene-environment interplay between cannabis and psychosis. Schizophr. Bull. 34, 1111\u20131121 (2008).","journal-title":"Schizophr. Bull."},{"key":"1330_CR22","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1146\/annurev-clinpsy-032813-153631","volume":"10","author":"R van Winkel","year":"2014","unstructured":"van Winkel, R. & Kuepper, R. Epidemiological, neurobiological, and genetic clues to the mechanisms linking cannabis use to risk for nonaffective psychosis. Annu. Rev. Clin. Psychol. 10, 767\u2013791 (2014).","journal-title":"Annu. Rev. Clin. Psychol."},{"key":"1330_CR23","doi-asserted-by":"crossref","unstructured":"Davis, K. A. S. et al. Mental health in UK Biobank \u2013 development, implementation and results from an online questionnaire completed by 157 366 participants: a reanalysis. BJPsych Open 6 (2020).","DOI":"10.1192\/bjo.2019.100"},{"key":"1330_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-11953-9","volume":"10","author":"Y Tanigawa","year":"2019","unstructured":"Tanigawa, Y. et al. Components of genetic associations across 2,138 phenotypes in the UK Biobank highlight adipocyte biology. Nat. Commun. 10, 4064 (2019).","journal-title":"Nat. Commun."},{"key":"1330_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-020-0794-x","volume":"10","author":"C Alloza","year":"2020","unstructured":"Alloza, C. et al. Psychotic-like experiences, polygenic risk scores for schizophrenia, and structural properties of the salience, default mode, and central-executive networks in healthy participants from UK Biobank. Transl. Psychiatry 10, 122 (2020).","journal-title":"Transl. Psychiatry"},{"key":"1330_CR26","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1038\/s41588-018-0059-2","volume":"50","author":"AF Pardi\u00f1as","year":"2018","unstructured":"Pardi\u00f1as, A. F. et al. Common schizophrenia alleles are enriched in mutation-intolerant genes and in regions under strong background selection. Nat. Genet. 50, 381\u2013389 (2018).","journal-title":"Nat. Genet."},{"key":"1330_CR27","doi-asserted-by":"crossref","unstructured":"Keller, M. C. Gene \u00d7 environment interaction studies have not properly controlled for potential confounders: the problem and the (simple) solution. Biol. Psychiatry 75, 18\u201324 (2014).","DOI":"10.1016\/j.biopsych.2013.09.006"},{"key":"1330_CR28","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1093\/schbul\/sbt181","volume":"40","author":"M Di Forti","year":"2014","unstructured":"Di Forti, M. et al. Daily use, especially of high-potency cannabis, drives the earlier onset of psychosis in cannabis users. Schizophr. Bull. 40, 1509\u20131517 (2014).","journal-title":"Schizophr. Bull."},{"key":"1330_CR29","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1038\/nrn2536","volume":"10","author":"PC Fletcher","year":"2009","unstructured":"Fletcher, P. C. & Frith, C. D. Perceiving is believing: a Bayesian approach to explaining the positive symptoms of schizophrenia. Nat. Rev. Neurosci. 10, 48\u201358 (2009).","journal-title":"Nat. Rev. Neurosci."},{"key":"1330_CR30","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.pneurobio.2010.06.007","volume":"92","author":"PR Corlett","year":"2010","unstructured":"Corlett, P. R., Taylor, J. R., Wang, X.-J., Fletcher, P. C. & Krystal, J. H. Toward a neurobiology of delusions. Prog. Neurobiol. 92, 345\u2013369 (2010).","journal-title":"Prog. Neurobiol."},{"key":"1330_CR31","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.1523\/JNEUROSCI.5603-07.2008","volume":"28","author":"KL Phan","year":"2008","unstructured":"Phan, K. L. et al. Cannabinoid modulation of amygdala reactivity to social signals of threat in humans. J. Neurosci. 28, 2313\u20132319 (2008).","journal-title":"J. Neurosci."},{"key":"1330_CR32","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1038\/mp.2016.21","volume":"22","author":"E van de Giessen","year":"2017","unstructured":"van de Giessen, E. et al. Deficits in striatal dopamine release in cannabis dependence. Mol. Psychiatry 22, 68\u201375 (2017).","journal-title":"Mol. Psychiatry"},{"key":"1330_CR33","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1111\/j.1460-9568.2006.05046.x","volume":"24","author":"G Cenni","year":"2006","unstructured":"Cenni, G. et al. Differential effect of cannabinoid agonists and endocannabinoids on histamine release from distinct regions of the rat brain. Eur. J. Neurosci. 24, 1633\u20131644 (2006).","journal-title":"Eur. J. Neurosci."},{"key":"1330_CR34","doi-asserted-by":"publisher","unstructured":"Gillespie, N. A. & Kendler, K. S. Use of genetically informed methods to clarify the nature of the association between cannabis use and risk for schizophrenia. JAMA Psychiatry https:\/\/doi.org\/10.1001\/jamapsychiatry.2020.3564 (2020).","DOI":"10.1001\/jamapsychiatry.2020.3564"},{"key":"1330_CR35","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1017\/S0033291716003172","volume":"47","author":"SH Gage","year":"2017","unstructured":"Gage, S. H. et al. Assessing causality in associations between cannabis use and schizophrenia risk: a two-sample Mendelian randomization study. Psychol. Med. 47, 971\u2013980 (2017).","journal-title":"Psychol. Med."},{"key":"1330_CR36","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1038\/mp.2016.252","volume":"23","author":"J Vaucher","year":"2018","unstructured":"Vaucher, J. et al. Cannabis use and risk of schizophrenia: a Mendelian randomization study. Mol. Psychiatry 23, 1287\u20131292 (2018).","journal-title":"Mol. Psychiatry"},{"key":"1330_CR37","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1038\/s41593-018-0206-1","volume":"21","author":"JA Pasman","year":"2018","unstructured":"Pasman, J. A. et al. GWAS of lifetime cannabis use reveals new risk loci, genetic overlap with psychiatric traits, and a causal effect of schizophrenia liability. Nat. Neurosci. 21, 1161\u20131170 (2018).","journal-title":"Nat. Neurosci."},{"key":"1330_CR38","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.schres.2017.04.016","volume":"194","author":"JY Khokhar","year":"2018","unstructured":"Khokhar, J. Y., Dwiel, L. L., Henricks, A. M., Doucette, W. T. & Green, A. I. The link between schizophrenia and substance use disorder: a unifying hypothesis. Schizophr. Res. 194, 78\u201385 (2018).","journal-title":"Schizophr. Res."},{"key":"1330_CR39","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.schres.2004.01.005","volume":"71","author":"MT Compton","year":"2004","unstructured":"Compton, M. T., Furman, A. C. & Kaslow, N. J. Lower negative symptom scores among cannabis-dependent patients with schizophrenia-spectrum disorders: preliminary evidence from an African American first-episode sample. Schizophr. Res. 71, 61\u201364 (2004).","journal-title":"Schizophr. Res."},{"key":"1330_CR40","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1080\/j.1440-1614.2006.01840.x","volume":"40","author":"D Schofield","year":"2006","unstructured":"Schofield, D. Reasons for cannabis use in psychosis. Aust. N. Z. J. Psychiatry 40, 570\u2013574 (2006).","journal-title":"Aust. N. Z. J. Psychiatry"},{"key":"1330_CR41","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1111\/eip.12112","volume":"9","author":"KE Gill","year":"2015","unstructured":"Gill, K. E. et al. Reasons for cannabis use among youths at ultra high risk for psychosis. Early Interv. Psychiatry 9, 207\u2013210 (2015).","journal-title":"Early Interv. Psychiatry"},{"key":"1330_CR42","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1093\/schbul\/sbq100","volume":"37","author":"J Gilleen","year":"2011","unstructured":"Gilleen, J., Greenwood, K. & David, A. S. Domains of awareness in schizophrenia. Schizophr. Bull. 37, 61\u201372 (2011).","journal-title":"Schizophr. Bull."},{"key":"1330_CR43","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/13546805.2011.562071","volume":"17","author":"N Bruno","year":"2012","unstructured":"Bruno, N., Sachs, N., Demily, C., Franck, N. & Pacherie, E. Delusions and metacognition in patients with schizophrenia. Cogn. Neuropsychiatry 17, 1\u201318 (2012).","journal-title":"Cogn. Neuropsychiatry"},{"key":"1330_CR44","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1017\/S003329171800226X","volume":"49","author":"HV Curran","year":"2019","unstructured":"Curran, H. V. et al. Which biological and self-report measures of cannabis use predict cannabis dependency and acute psychotic-like effects? Psychol. Med. 49, 1574\u20131580 (2019).","journal-title":"Psychol. Med."},{"key":"1330_CR45","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1192\/bjp.bp.109.064220","volume":"195","author":"MD Forti","year":"2009","unstructured":"Forti, M. D. et al. High-potency cannabis and the risk of psychosis. Br. J. Psychiatry 195, 488\u2013491 (2009).","journal-title":"Br. J. Psychiatry"},{"key":"1330_CR46","doi-asserted-by":"publisher","first-page":"204512531988191","DOI":"10.1177\/2045125319881916","volume":"9","author":"C Davies","year":"2019","unstructured":"Davies, C. & Bhattacharyya, S. Cannabidiol as a potential treatment for psychosis. Ther. Adv. Psychopharmacol. 9, 2045125319881916 (2019).","journal-title":"Ther. Adv. Psychopharmacol."},{"key":"1330_CR47","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1001\/jamapsychiatry.2018.2309","volume":"75","author":"S Bhattacharyya","year":"2018","unstructured":"Bhattacharyya, S. et al. Effect of cannabidiol on medial temporal, midbrain, and striatal dysfunction in people at clinical high risk of psychosis: a randomized clinical trial. JAMA Psychiatry 75, 1107\u20131117 (2018).","journal-title":"JAMA Psychiatry"},{"key":"1330_CR48","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1176\/appi.ajp.2017.17030325","volume":"175","author":"P McGuire","year":"2018","unstructured":"McGuire, P. et al. Cannabidiol (CBD) as an adjunctive therapy in schizophrenia: a multicenter randomized controlled trial. Am. J. Psychiatry 175, 225\u2013231 (2018).","journal-title":"Am. J. Psychiatry"},{"key":"1330_CR49","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/S2215-0366(20)30074-2","volume":"7","author":"G Hindley","year":"2020","unstructured":"Hindley, G. et al. Psychiatric symptoms caused by cannabis constituents: a systematic review and meta-analysis. Lancet Psychiatry 7, 344\u2013353 (2020).","journal-title":"Lancet Psychiatry"},{"key":"1330_CR50","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.schres.2011.04.017","volume":"130","author":"CD Schubart","year":"2011","unstructured":"Schubart, C. D. et al. Cannabis with high cannabidiol content is associated with fewer psychotic experiences. Schizophr. Res. 130, 216\u2013221 (2011).","journal-title":"Schizophr. Res."},{"key":"1330_CR51","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1176\/ajp.155.3.350","volume":"155","author":"JP Selten","year":"1998","unstructured":"Selten, J. P., Gernaat, H. B., Nolen, W. A., Wiersma, D. & van den Bosch, R. J. Experience of negative symptoms: comparison of schizophrenic patients to patients with a depressive disorder and to normal subjects. Am. J. Psychiatry 155, 350\u2013354 (1998).","journal-title":"Am. J. Psychiatry"}],"container-title":["Translational Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41398-021-01330-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41398-021-01330-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41398-021-01330-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T12:55:08Z","timestamp":1669899308000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41398-021-01330-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,9]]},"references-count":51,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,6]]}},"alternative-id":["1330"],"URL":"https:\/\/doi.org\/10.1038\/s41398-021-01330-w","relation":{},"ISSN":["2158-3188"],"issn-type":[{"value":"2158-3188","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,9]]},"assertion":[{"value":"18 January 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"211"}}